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Abstract
Background: The T-box transcription factor TBX3 is necessary for early embryonic development and for the normal
development of the mammary gland. Homozygous mutations, in mice, are embryonic lethal while heterozygous
mutations result in perturbed mammary gland development. In humans, mutations that result in the
haploinsufficiency of TBX3 causes Ulnar Mammary Syndrome (UMS) characterized by mammary gland hypoplasia
as well as other congenital defects. In addition to its role in mammary gland development, various studies have
also supported a role for Tbx3 in breast cancer development. TBX3 is over-expressed in various breast cancer cell
lines as well as cancer tissue and has been found to contribute to breast cancer cell migration. Previous studies
have suggested that TBX3 contributes to cancer development by its ability to bypass senescence by repressing the
expression of p14
ARF-tumor suppressor. Although many studies have shown that a dysregulation of TBX3
expression may contribute to cancer progression, no direct evidence shows TBX3 causes breast cancer.
Results: In this study, we created doxycycline inducible double transgenic mice (MMTV-rtTA;tet-myc-TBX3-IRES-
Luciferase) to test whether TBX3 over-expression can induce tumor formation within the mammary gland.
Although over-expression of TBX3, alone, did not induce tumor formation it did promote accelerated mammary
gland development by increasing mammary epithelial cell proliferation. We also show that TBX3 directly binds to
and represses NFBIB, an inhibitor of the NF-B pathway known to play a role in regulating cell proliferation. Lastly,
we also show that the over-expression of TBX3 is associated with an increase in mammary stem-like cells.
Conclusions: Overall, our data suggests that over-expression of TBX3 may contribute to breast cancer
development by promoting accelerated mammary gland development through the inhibition of the NF-B
pathway and stimulation of both mammary epithelial cell and stem-like cell proliferation.
Background
TBX3 is a member of the T-box family of genes. T-box
genes are expressed during embryonic development and
have been found to regulate cell specification and orga-
nogenesis [1,2]. They are also well-known for the roles
they play in many human developmental syndromes
[3-6]. Tbx3 is known to function as a transcriptional
repressor and is required for embryonic development
and for the normal development of the mammary gland
[7-11]. In mice models, homozygous mutations in which
the function of Tbx3 is completely lost are embryonic
lethal while haploinsufficiency of Tbx3 results in signifi-
cantly reduced branching of ductal trees in adult ani-
mals [12]. In humans, mutations that result in the
haploinsufficiency and loss of function of TBX3 ulti-
mately cause Ulnar Mammary Syndrome (UMS)
[3,13,14]. UMS is an autosomal dominant disorder char-
acterized by mammary gland hypoplasia and affects
limb, apocrine-gland, teeth, hair, and genital develop-
ment. Besides Tbx3’s role in early mammary gland
development, various studies have also supported a role
for Tbx3 in breast cancer development. The TBX3 gene
is located at the 12q24 region which is frequently ampli-
fied in a variety of malignancies including breast cancer
[7,15]. Moreover, TBX3 is over-expressed in various
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any medium, provided the original work is properly cited.breast cancer cell lines as well as primary breast cancer
tissues [16,17]. TBX3 is mislocalized to the cytoplasm in
primary breast cancer tissues and serum TBX3 protein
levels were also found to be abnormally high in early
stage breast cancer patients [17,18]. More recently, it
has been shown that PMA-induced up-regulation of
TBX3 contributes to breast cancer cell migration [19].
TBX3 has been shown to repress the expression of the
tumor suppression gene p14
ARF [8,9,11,20] and the mur-
ine homologue p19
ARF [8]. The p14/19(ARF)-Mdm2-p53
pathway plays an important role in regulating cell senes-
cence and protects cells against oncogenic transforma-
tion which leads to tumor formation [8,9,11,20]. TBX3
over-expression has been shown to immortalize mouse
embryonic fibroblast cells by suppressing p19
ARF
[8,16,21]. We have previously shown that over-expres-
sion of TBX3 represses human p14
ARF by recruiting
HDAC 1, 2, 3 and 5 in the MCF7 breast cancer cell line
[17]. In order to identify other targets of TBX3, we used
chromatin immunoprecipitation-guided ligation and
selection (ChIP-GLAS) promoter array. Our results
showed that 430 gene promoters are bound by TBX3 in
the MCF7 breast cancer cell line (unpublished data).
One of the identified genes, NFBIB,i sa ni n h i b i t o ro f
NF-B. Studies have shown that NF-B associated path-
ways play an important role in cell proliferation, differ-
entiation and apoptosis [22]. Specifically, NFBIB
inhibits NF-B by sequestering it in the cytoplasm. Acti-
vation of NF-B occurs upon ubiquitin mediated degra-
dation of NFBIB proteins via serine phosphorylation by
IB kinase (IKK). Studies have shown that inhibition of
NF-B activation in mouse mammary glands lead to
defective proliferation in lobuloalveolar structures dur-
ing pregnancy [23], whereas elevated NF-B activity
causes mammary hyperplasia in vivo [24]. Furthermore,
aberrant activation of NF-B is related to breast cancer
progression, including tumor initiation, proliferation,
chemoresistance and tumor metastasis [25]. Taken
together, these studies suggest that a dysregulation of
TBX3 expression may contribute to breast cancer
development.
Further supporting the notion that Tbx3 plays a role
in cancer development, recent studies have shown that
increased levels of TBX3 enhanced melanoma invasive-
ness by repressing E-cadherin expression [26]. Recent
studies have shown that TBX3, a downstream target of
Wnt/b-catenin in liver cancer, has also been found to be
over-expressed in human hepatocellular carcinoma and
heptoblastoma [27]. Knockdown of Tbx3 in rat bladder
carcinoma cell lines resulted in a lower growth rate and
more apoptotic cells than controls, suggesting that Tbx3
promotes cell proliferation and is a negative regulator of
apoptosis [28]. Although many studies have shown that
a dysregulation of TBX3 expression may contribute to
cancer progression, no direct evidence shows that TBX3
causes breast cancer.
Identifying whether TBX3 directly promotes breast
cancer development and the mechanism by which it
does this is important for understanding mammary
development as well as the perturbations that may lead
to breast cancer. In the present study, we have demon-
strated that over-expression of TBX3 in our doxycycline
inducible mouse model promotes accelerated mammary
gland development and hyperplasia by promoting mam-
mary epithelium cell proliferation. Moreover, we have
shown that NFBIB was dramatically down-regulated in
the mammary glands of doxycycline induced double
transgenic mice. Although over-expression of TBX3,
alone, did not cause tumor formation within the mam-
mary gland, our data suggests that the over-expression
of TBX3 may contribute to breast cancer formation
through the inhibition of the NF-B pathway and stimu-
lation of both mammary epithelial cell and stem-like cell
proliferation.
Results
TBX3 over-expression is induced in MMTV-rtTA; tet-myc-
TBX3 mammary glands by doxycycline administration
To construct a doxycycline inducible myc-TBX3 trans-
gene cassette (TMILA-myc-TBX3-IRES-Luciferase),
myc-TBX3 cDNA was subcloned downstream of tet
operator elements (TetO) (Figure 1A). In our transgene
expression cassette, the expression of the luciferase
reporter gene is regulated by the same promoter as our
myc-TBX3 transgene. Thus, upon induction with doxy-
cycline, translation of the luciferase reporter gene by its
own internal ribosome entry site (IRES) can be used as
a marker for myc-TBX3 overexpression (Figure 1A). In
order to express myc-TBX3 specifically in the mammary
glands of mice, tet-myc-TBX3 mice were mated with
MMTV-rtTA mice. Transgene expression was induced
in double transgenic mice by adding 2mg/ml doxycy-
cline to the drinking water. To verify that the induction
of TBX3 expression within the mammary glands of mice
occurred only upon the addition of doxycycline, lucifer-
ase activity was monitored by imaging the mammary
glands of both doxycycline induced and un-induced
double transgenic mice in vivo, using an ICCD camera.
Prior to in vivo imaging, mice were sedated by intraperi-
toneal injection of Xylazine and Ketamine. After 5 min-
utes, an aqueous solution of luciferin was injected into
the peritoneal cavity to detect luciferase activity and
TBX3 transgene over-expression. The in vivo image of
the doxycycline induced double transgenic mouse
detected a bioluminescent signal 4-200 folds above
background within all 5 pairs of mammary glands. The
bright bioluminescent signal in the cervical midline of
the doxycycline induced double transgenic mouse
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leaky expression of the MMTV promoter within the
salivary gland, which is frequently seen in other MMTV
models (Figure 1B). No signal was detected in the age-
matched un-induced double transgenic littermate con-
trol (Figure 1B, left panel). To more directly measure
the luciferase activity within each mammary gland a
luciferase assay was performed using tissue lysates from
each mammary gland (1-5) of a single doxycycline
induced double transgenic mouse (n = 1). Consistent
with the in vivo imaging, all five mammary glands from
the doxycycline induced double transgenic mice had
high luciferase readings while the un-induced double
transgenic littermates showed only baseline readings
(Figure 1B, right panel). Direct TBX3 over-expression
within the mammary gland was also detected by immu-
nohistochemistry with an anti-TBX3 antibody. TBX3
over-expression was detected only in the induced double
transgenic mouse mammary gland (Figure 1C). Endo-
genous TBX3 expression was not detected (Figure 1C,
right panel). Overall, these results show that TBX3 over-
expression is specifically induced within all 5 mammary
Figure 1 TBX3 transgene expression is tightly controlled by doxycycline administration within mammary glands of double-transgenic
mice. A) Diagram of tetracycline inducible TBX3 transgene cassette. In the presence of doxycycline, the tetracycline reverse transcriptional
activator (rtTA), expressed in mammary epithelium, binds to the tetracycline-operator (Tet-On), which in turn activates the transcription of TBX3
and firefly luciferase. B) Left panel: In vivo detection of luciferase reporter activity. Fifteen-week old doxycycline induced and un-induced double
transgenic female mice were injected with an aqueous solution of luciferin into the peritoneal cavity. Images were taken with an ICCD camera
five minutes later. Right panel: Luciferase reporter activity in tet-TBX3; MMTV-rtTA transgenic mammary glands. Mammary glands from
doxycycline induced and un-induced double transgenic mice were dissected and lysates were prepared. The luciferase activity of 10μl of total
protein lysate was measured. Numbers on X-axis indicate the pair of mammary gland used in the assay (n = 1). C) Immunohistochemical analysis
of TBX3 expression in doxycycline induced and un-induced double transgenic littermates at 10 weeks of age. Images were captured at 40×
magnification.
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tion of doxycycline.
Over-expression of TBX3 promotes accelerated mammary
gland development by increasing cell proliferation
In mice, the mammary gland development begins
shortly after mid-gestation. Five pairs of mammary pla-
codes form at the site of the future nipples [29]. These
placodes invaginate and form buds within the mammary
fat pad that contain few branches [29]. By birth a simple
mammary ductal tree is formed that occupies a small
portion of the fat pad [30]. After birth, growth of the
mammary gland is relatively quiescent until puberty
[31]. At puberty, club-shaped structures called the term-
inal end buds (TEBs) form at the tips of the ductal tree.
During this period, cell proliferation in TEBs results in
ductal elongation through the mammary fat pad. TEBs
not only elongate through the fat pad, but also bifurcate
to form new primary ducts while secondary side-
branches sprout along the extending ducts [31]. The
outgrowth of side branches is controlled by several hor-
mones and signaling pathways [29]. At the end of pub-
erty, approximately 10-12 weeks of age, TEBs reach the
edge of the fat pad and disappear [31,32]. In order to
determine the effect of TBX3 over-expression on the
overall development of the mammary gland, we har-
vested the 1st and 4th mammary glands from 3 doxycy-
cline induced double transgenic mice and from another
3 of the un-induced double transgenic littermate con-
trols at four specific time points; 7-weeks, 10-weeks, 12-
weeks of age and 10.5 days postcoitus (dpc). Mammary
glands harvested at 7-weeks, 10-weeks and 12-weeks
were from nulliparous mice, while those harvested at
10.5 dpc were from uniparous pregnant mice. Whole
mount analysis of the 4
th mammary gland revealed that
at 7-weeks and 10-weeks of age, TEBs in the control
mice had not reached the edge of the fat pad, whereas
the TEBs in doxycycline induced double transgenic mice
were observed at the edge of the fat pad or had disap-
peared (Figure 2A, arrows indicate TEBs), suggesting
that over-expression of TBX3 promotes accelerated duc-
tal elongation. Hematoxylin and eosin staining of both
the 1
st and 4
th mammary glands of the doxycycline
induced double transgenic mice displayed increased pri-
mary and secondary side branching at all time points
when compared to their un-induced double transgenic
littermate controls (Figure 2A and 2B). We also
observed an increase in tertiary side branching although
this has been known to occur in response to estrous
cycle [29]. In addition, pregnant doxycycline induced
double transgenic mice at 10.5 dpc also displayed more
alveoli tissue than the un-induced double transgenic
controls (Figure 2A and 2B). The samples used for
whole mount analysis were from two independent
founder lines and the results were consistent between
these two lines.
Several in vitro studies have suggested that the over-
expression of Tbx3/TBX3 leads to the bypass of senes-
cence and promotes cell proliferation [8,16,21,33,34]. To
determine whether the observed accelerated develop-
ment of the mammary glands in TBX3 over-expressing
mice is due to an increase in cell proliferation, we per-
formed an EdU cell proliferation assay. The 4th mam-
mary glands from pregnant doxycycline induced and
un-induced double transgenic mice were harvested at
10.5 dpc and used for the assay. The proportion of
nucleated cells incorporating EdU was quantified by
fluorescence microscopy (Figure 3A) and normalized to
the total cell number in each 20× field. After quantifica-
tion, we found that the percentage of Edu positive cells
is significantly (p < 000.1) higher in mammary glands
over-expressing TBX3, than their un-induced controls
(Figure 3B). This result suggests that over-expression of
TBX3 may promote accelerated mammary gland devel-
opment by promoting mammary epithelial cell prolifera-
tion in vivo.
Since highly proliferative tissues are associated with
carcinogenesis, we next analysed the histology of the 3
rd
mammary glands of 15 week old mice to identify if any
unusual morphological changes have occurred. Hema-
toxylin and eosin staining of the doxycycline induced
double transgenic mouse mammary gland showed mild
focal hyperplasia (Figure 2B, arrows) and discontinued
ductal epithelium (Figure 2B, arrowheads) when com-
pared to the littermate control. By the age of 20 months,
none of the doxycycline induced double transgenic mice
had developed tumors.
TBX3 represses NFBIB
In our double transgenic mouse model in which TBX3
was over-expressed, we observed accelerated develop-
ment of the mammary gland from 7 weeks of age
through pregnancy; specifically enhanced branching and
ductal elongation. Moreover mice that over-expressed
TBX3 also had a significantly higher percentage of pro-
liferating mammary epithelial cells than controls.
Together these data suggest that TBX3 may be regulat-
ing genes that play a role in cell proliferation. Identify-
ing the mechanism by which TBX3 promotes
accelerated mammary gland development will help to
further elucidate its possible role in breast cancer devel-
opment. Dysregulation of the NF-Ba s s o c i a t e dp a t h -
ways have been shown to play a role in breast cancer
development [35]. Moreover, it has been shown that ele-
vated NF-B activity causes mammary hyperplasia in
vivo [24]. Due to this observed phenotype and our pre-
vious unpublished data in which TBX3 binds to the pro-
moter of NFBIB in MCF7 cells, we investigated the
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To verify that TBX3 does indeed regulate the NFBIB
promoter, we performed a luciferase assay. Briefly, COS-
7 cells were transfected with either pcDNA3.1-Myc
(control) or pcDNA3.1-Myc-TBX3 expression vector
together with the pGL3-NFBIB luciferase reporter
construct and a b-galactosidase control plasmid
(pcDNA3.1/His/LacZ) using Lipofectamine 2000. Forty-
eight hours later, cell lysates were harvested and used to
perform the luciferase assay. b-galactosidase enzyme
activity was measured and used to normalize luciferase
activity. The luciferase assay revealed that the activity of
Figure 2 TBX3 over-expression causes accelerated mammary gland development and hyperplasia. A) Whole mount analysis of the 4th
mammary gland from 7-weeks, 10-weeks, 12-weeks old virgin mice and day 10.5 dpc pregnant mice. Acceleration of mammary gland
development is observed in doxycycline induced double transgenic mice from 7 to 12 weeks of age. TEBs are present in un-induced control
mice at 7- and 10- weeks of age (arrows), whereas TEBs in doxycycline induced double transgenic mice pass the fat pad and start to disappear.
At all time points, branching morphogenesis was promoted in the doxycycline induced double transgenic mice. Representative whole mount of
the 4th mammary gland from 10.5 dpc pregnant un-induced double transgenic mouse has less alveoli tissue than the 4th mammary gland from
day 10.5 dpc pregnant doxycycline induced double transgenic mouse (n = 3). All images were captured at 5× magnification. Image insets were
captured at 20× magnification. B) Whole mount analysis of the 1st mammary gland from un-induced double transgenic mice and doxycycline
induced double transgenic mice at 12 weeks of age and pregnant 10.5 dpc. Mammary glands from doxycycline induced double transgenic mice
displayed enhanced side branching and advanced development of alveolar structure. Images were captured at 10× magnification. Hematoxylin
and eosin stain performed on the 3rd mammary gland of doxycycline induced and un-induced double transgenic mice at 15 weeks of age
showed mild hyperplasia (arrows) and disturbed organization in the mammary epithelium (arrowheads) (n = 3). Images were captured at 40×
magnification.
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0.0001) when TBX3 is over-expressed in COS-7 cells
(Figure 4A). To determine whether the Nfbib protein
was down-regulated upon over-expression of TBX3
within the mammary gland, immunohistochemistry was
performed on the mammary glands of doxycycline
induced and un-induced double transgenic mice at 10
weeks of age. Staining revealed the Nfbib expression
was down-regulated in the doxycycline induced double
transgenic mouse when compared to its un-induced
double transgenic littermate control (Figure 4B). These
data suggest that over-expression of TBX3 may promote
cell proliferation within the mammary gland by repres-
sing the expression of Nfbib.
Over-expression of TBX3 is associated with an increase in
mammary stem-like cells
Another mechanism by which TBX3 over-expression
may promote accelerated mammary gland development
is through the proliferation of mammary stem cells.
Expression of Tbx3 has been shown to promote the pro-
liferation of breast cancer stem cells in vitro [36], sug-
gesting that Tbx3 may also promote mammary stem cell
proliferation. A study showed that a single Lin
-CD24
+CD29
high cell is able to generate a functional mammary
gland, providing strong evidence that these cells are
mammary stem cells [37]. Thus, to isolate and analyze
the mammary stem-like cell population we first sub-
tracted the mammary Lin
+ (CD31
+, CD45
+ and TER119
+) cells. CD31 is considered as an endothelial cell mar-
ker, and CD45 and TER119 are considered as hemato-
poietic cell markers [37]. Therefore, Lin
+ (CD31
+, CD45
+ and TER119
+) cells are considered a terminally differ-
entiated cell population. In contrast, CD29 is a skin
stem cell marker [38] and CD24 is found on neuronal
stem cells [39], therefore CD29
+ and CD24
+ cells are
considered mammary stem-like cells [37]. To determine
whether over-expression of TBX3 promotes the prolif-
eration of mammary stem-like cells, we dissected mam-
mary glands from two mice at 12 weeks of age from the
Figure 3 TBX3 over-expression promotes cell proliferation. A) Edu cell proliferation assay. The fourth mammary glands from doxycycline
induced and un-induced double transgenic mice were harvested at 10.5 dpc and 5μm thick sections were embedded in paraffin and subjected
to the Click-iT EdU proliferation Assay (Promega). EdU that had been incorporated into newly synthesized DNA was detected by Alexa Fluor 594
azide (red) and cell nuclei were stained with Hoechst 33342 (blue). All Images were captured at 20× magnification. B) Quantification of Edu
positive cells. Fifteen random 20× fields were taken from each group of litter matched doxycycline induced and un-induced double transgenic
mice. The proliferating cells were quantified and normalized to the total cell number in each field. The graph is generated from the average
ratio (Edu/Hoechst) of fifteen 20× fields in each group. Error bars indicate SD; n = 1. **,P < 0.001.
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un-induced double transgenic littermates and isolated
the mammary stem-like cells using the previously men-
tioned cell markers. The gating strategy for Lin
- cells
and CD24
+ CD29
high c e l l si ss h o w ni nF i g u r e5 A .F A C s
analysis revealed that over-expression of TBX3 did not
affect the overall frequency of Lin
- cells in the mammary
glands of doxycycline induced and un-induced mice,
35.92% and 33.15%, respectively (Figure 5A). However,
within the Lin
- population, there was a significant
increase in the frequency of CD24
+CD29
high cells in the
doxycycline induced double transgenic mice versus un-
induced control; 17.37% and 9.17% respectively (p <
0.05) (Figure 5A and 5B). The average and standard
deviations from both mice in each group are presented
in Figure 5B. These results suggest that over-expression
of TBX3 may promote proliferation of mammary stem-
like cells.
Discussion
The TBX3 T-box transcription factor plays an important
role in early mammary development [3,7,12,40]. Muta-
tions that cause haploinsufficiency of Tbx3 result in
mammary gland hypoplasia in both mice and human
Figure 4 TBX3 inhibits NFKBIB promoter activity. A) Luciferase reporter assay. COS-7 cells were transfected with either pcDNA3.1-Myc
(control) or pcDNA3.1-Myc-TBX3 expression vectors together with the pGL3-NFBIB luciferase reporter construct and a b-galactosidase control
plasmid (pcDNA3.1/His/LacZ). Cell lysates were harvested 48 hours after transfection and used to measure luciferase activity. b-galactosidase
enzyme activity was also measured and used to normalize luciferase activity. Error bars indicate SD; n = 3. **, P < 0.001. B) Immunohistochemical
staining of Nfbib in doxycycline induced and un-induced double transgenic mice at 10 weeks of age. The third mammary glands were fixed
and embedded in paraffin. Five micrometer thick sections were blocked with hydrogen peroxide and incubated with rabbit anti-Nfbib antibody
overnight. Biotinylated goat anti-rabbit IgG was used as a secondary antibody. Standard ABC kit and DAB kit were used for visualization. Nfbib
was down-regulated in the doxycycline induced double transgenic mouse as compared to its un-induced double transgenic littermate control.
Images were captured at 40× magnification.
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a variety of cancers, including breast cancer
[16,18,26,28]. Although Tbx3 over-expression has been
associated with oncogenesis by its known ability to inhi-
bit P14
ARF expression and bypass senescence or by con-
tributing to breast cancer cell migration [11,17,19], no
direct evidence has been shown to suggest that over-
expression of TBX3, alone, can induce tumor formation
within the mammary gland. In this study, we over-
expressed TBX3 within the mammary glands of mice,
using a tissue-specific, doxycycline inducible transgenic
system. Transgenic mouse models using constitutive
promoters have provided information about specific
genes and breast cancer development, particularly onco-
gene function [41,42]. However, there are significant
limitations to these systems due to the lack of control of
transgene expression. The ability to control TBX3
expression is critical since homozygous Tbx3 knockout
is embryonic lethal and constitutive over-expression is
potentially toxic [12,43]. We implemented a Tet-On sys-
tem in our transgenic mouse model so that TBX3 trans-
gene expression is inducible in a time and tissue-specific
manner [44], enabling us to test possible TBX3 function
in tumorigenesis in the mammary glands. An advantage
of our mouse model is the ability to use luciferase
expression as an indication of TBX3 transgene expres-
sion (Figure 1A). In this way, we are able to monitor
TBX3 expression without sacrificing the animal. Using
in vivo imaging as well as a luciferase assay, we were
able to show that transgene expression is tightly con-
trolled by doxycycline administration (Figure 1B). Our
results show that this system is reliable and transgene
expression could be induced in all five pairs of mam-
mary glands.
Previous studies have shown that the five pairs of
mouse mammary glands are differentially regulated by
Tbx3 during early development. For example, in Tbx3
knockout studies, homozygous mutations resulted in the
absence of mammary placodes, except for an occasional
induction of the second pair of mammary placodes [12].
Heterozygous mutations of Tbx3 caused decreased
branching morphogenesis in the first three pairs of
mammary glands, but had no significant impact on the
fourth and fifth pairs of mammary glands [12]. In 18.5
day old Tbx3 heterozygous embryos, 75% of the first
pair of mammary glands was missing with no nipple or
ductal tree formation while the second pair of mammary
glands was affected to a lesser extent [21]. Although
these studies suggest that Tbx3 regulates murine mam-
mary glands differently, we found that over-expression
of TBX3 promotes accelerated mammary gland develop-
ment in both the first and fourth mammary glands (Fig-
ure 2A and 2B) as well as the second, third and fifth
mammary glands (data not shown).
Research has solidified a role for Tbx3 in the early
development of the mammary gland. Tbx3 homozygous
Figure 5 TBX3 over-expression is associated with increased mammary stem-like cell population.Aa n dB )F A C Sa n a l y s i so fm a m m a r y
stem-like cells. (A) Representative graphs of gating strategies used to select Lin
- from Lin
+ cell population. Anti-CD31, anti-CD45 and anti-TER119
antibodies were used to separate the Lin
- and Lin
+ cells from harvested mammary glands of 12-week old female virgin mice (doxycycline
induced and un-induced double transgenic littermates) (left panel). Gating strategy used to purify CD29
highCD24
+ cells from Lin
- cell population
(right panel). B) Statistical analysis of the average frequency of mammary stem-like cells (CD29
high, CD24
+) in Lin
- population. Two mice from
each group were used to generate the data. Error bars indicate SD; n = 2, *, P < 0.05.
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heterozygous mutations of Tbx3 caused decreased
branching morphogenesis in mammary glands [12,21].
Our research complements these previous studies show-
ing that TBX3 over-expression within the mammary
glands causes hyperplasia, promoting increased second-
ary and tertiary branching as well as accelerated ductal
elongation. It is also important to discuss that we have
over-expressed human TBX3 within the mammary
glands of mice. It has been shown that human TBX3
and mouse Tbx3 are 97% homologous at the protein
level. Our group and others have demonstrated that
human TBX3 is functional in mouse cells [9,12,16,20].
Furthermore, aTbx3 knockout mouse model was able to
recapitulate the phenotype seen in humans with Ulnar
Mammary Syndrome (UMS). In a study performed by
Papaioannou et al., a mutation in the mouse Tbx3 gene
that closely corresponds to truncation mutations seen in
some individuals with UMS resulted in a deficiency in
mammary placode induction and the absence or reduc-
tion of mammary buds in mutant embryos, correspond-
ing to the mammary gland hypoplasia seen in patients
with UMS. Moreover, the deficiency in the development
of limb elements in individuals with UMS was also
reflected in limb abnormalities in the Tbx3 mutant
mice. Mutant mice had deformities in the forelimb
digits, foot and fibula resulting from a failure in the
development of posterior limb elements. This study
exemplifies that the Tbx3 protein plays a similar role in
the development of the mammary glands in both
human and mice. The mechanism by which TBX3 over-
expression promotes hyperplasia in mammary glands
needs to be elucidated. Using an Edu cell proliferation
assay, we showed that over-expression of TBX3 resulted
i nad r a m a t i ci n c r e a s ei nc e l l proliferation within the
mammary glands of pregnant doxycycline induced dou-
ble transgenic mice at 10.5 dpc (Figure 3). Although cell
proliferation was not directly quantified for the other
developmental time points (i.e. 7-weeks, 10-weeks, and
12-weeks), the similarity in the observed accelerated
mammary gland development suggests that the increase
in cell proliferation at 10.5 dpc may also play a role in
causing the accelerated branching and elongation of
ducts during the other phases of mammary gland
growth. A study has shown that mammary epithelia
lacking the gene encoding NFBIA contained increased
NFkB activity as well as increased ductal branching and
widespread intraductal hyperplasia [24], similar to
results seen in our study. Furthermore, aberrant activa-
tion of NF-B increased cell proliferation and breast
cancer progression [25]. In this study, we found that
TBX3 inhibits the promoter activity of NFBIB in vitro
(Figure 4A). Upon further analysis, in vivo, we observed
that Nfbib expression was dramatically reduced in
doxycycline induced double transgenic mice as com-
pared to its un-induced double transgenic littermate
controls (Figure 4B). Taken together, our results suggest
am e c h a n i s mb yw h i c hT B X 3o v e r-expression represses
NFKBIB/Nfkbib expression to enhance cell proliferation
and promote mammary gland hyperplasia. However,
TBX3 is a multifunctional transcription factor and the
NFkB pathway could be one of many pathways regu-
lated by TBX3. Wnt signaling has also been shown to
play a major role in regulating mammary gland develop-
ment [27]. A TBX3
-/- mouse model lacked expression of
LEF1 and Wnt10b [12], suggesting that Wnt signaling is
a downstream target of TBX3 and that TBX3 may regu-
late mammary gland development via the Wnt signaling
pathway. Additional experiments can be done to further
elucidate other mechanisms by which TBX3 over-
expression promotes mammary hyperplasia.
Studies have suggested a role for Tbx3/TBX3 in regu-
lating the self-renewal of mouse embryonic stem (ES)
cells as well as breast cancer stem-like cells [36,45-47].
Mouse ES cells require leukemia inhibitory factor (LIF)
to maintain their undifferentiated state [48]. Mouse ES
cells genetically modified to over-express Tbx3 and
grown in culture without LIF were able to maintain
their undifferentiated state [47]. Knockdown of Tbx3
expression in mouse ES cells resulted in a loss of self-
renewal, causing these cells to differentiate [45]. These
findings suggest that Tbx3 expression is necessary to
maintain mouse ES cells in their undifferentiated state
and plays a functional role to promote self-renewal. A
recent study has proposed a model in which the expres-
sion of TBX3 in cancer cells promotes the expansion of
cancer stem-like cells through paracrine fibroblast
growth factor (FGF) signaling [36]. Over-expression of
TBX3 increased the proportion of cancer stem-like cells
in MCF7 cells by nine-fold as well as lead to an increase
in tumorsphere formation and tumor initiation [36],
suggesting that TBX3 is sufficient to promote normal
and cancer stem like cell phenotypes. Due to its role in
promoting proliferation of mouse ES cells and breast
cancer stem-like cells as well as its requirement for early
mammary gland development, TBX3 may also play a
role in regulating mammary stem cell proliferation.
Mammary glands consist of two cell lineages: myoe-
pithelial and luminal epithelial cells. Both of them arise
from a common progenitor, the mammary stem cell.
Research has shown that a single Lin
-CD24
+CD29
high
cell is able to generate a functional mammary gland,
suggesting that these cells are mammary stem cells [37].
To determine whether over-expression of TBX3 affects
mammary stem cell proliferation, we performed FACS
analysis of the stem-like cell population, Lin
-CD24
+CD29
high, in doxycycline induced double transgenic
mice and their un-induced littermate controls. We
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increased the frequency of Lin
-CD24
+CD29
high stem-like
cell population (Figure 5A and 5B), indicating that
TBX3 expression is associated with an increased number
of mammary stem-like cells. This could explain another
mechanism by which TBX3 over-expression can cause
hyperplasia and accelerated mammary gland develop-
ment. Further studies of the mechanisms by which
TBX3 regulates mammary stem-like cells are required
to improve our understanding of mammary gland devel-
opment and TBX3 function.
Conclusions
TBX3 over-expression causes mammary gland hyperpla-
sia possibly by inhibiting NFBIB expression and thus
promoting cell proliferation. Also, over-expression of
TBX3 is associated with an increased number of mam-
mary stem-like cells suggesting another mechanism by
which TBX3 may promote mammary gland hyperplasia
and contribute to breast cancer development.
Methods
Plasmid construction
To generate the Tet-on inducible N-myc-TBX3 expres-
sion cassette (tet-N-myc-TBX3-IRES-Luciferase), the
full-length human TBX3 cDNA fused with the N-myc
tag was subcloned from the expression vector, pcDNA-
myc-TBX3, into the ClaI and SpeI sites of the TMILA
plasmid, downstream of an inducible tetracycline pro-
moter (Figure 1A). Correct insertion of the N-myc-
TBX3 transgene into the TMILA plasmid was verified
by sequencing.
Generation and PCR-genotyping of transgenic mice
To generate doxycycline inducible myc-TBX3 transgenic
mice, the N-myc-TBX3 expression cassette (tet-myc-
TBX3-IRES-luciferase) was cut out from the TMILA-
myc-TBX3 plasmid using the PvuII restriction enzyme
to remove the plasmid backbone. The fragment was gel-
purified using the Qiagen Gel Extraction Kit (Valencia,
CA) and filtered using a 0.1 micron filter. The purified
DNA fragment was then diluted with injection buffer to
a2 n g / μl concentration and microinjected at the UCI
Transgenic Mouse Facility. A total of 176 fertilized eggs
(obtained from FVB/N egg donors that were mated with
fertile males) were injected. One-hundred-sixty-five eggs
were implanted in the oviducts of pseudopregnant foster
mothers. From these, a total of 43 pups were obtained.
Potential founders were identified by PCR-based geno-
typing using a pTMILA and TBX3 gene specific primer
set (forward; 5’- CGCGCAATTAACCCTCACTA-3’
(pTMILA), reverse; 5’-AGGAATGACCGGATCTCTCA-
3’ (TBX3)). A total of 8 pups carrying the N-myc-TBX3
expression cassette were used as founders to cross with
established MMTV-rtTA mice to create double trans-
genic mice (MMTV-rtTA; tet-myc-TBX3-IRES-
Luciferase).
Doxycycline administration
Transgene expression was induced by adding 2 mg/ml
doxycycline to the drinking water from weaning age (3-
4 weeks) as previously described [44]. All mice involved
in the experiments were examined weekly for palpable
tumor formation.
In vivo imaging of Tet-on inducible TBX3 luciferase
reporter system
For in vivo mouse imaging, a cooled ICCD camera was
placed on top of a light-tight box. Prior to imaging,
mice were sedated by intraperitoneal injection (i.p.) of
250 ng Xylazine and 2 mg Ketamine. After 5 minutes,
an aqueous solution of luciferin (BioSynth, 150 mg/ml)
was injected into the peritoneal cavity at 150 mg/kg
body weight. An LED light, placed around the camera,
was first turned on to acquire body surface reference
images. At this time the field of view (F.O.V), focus and
f/stop were adjusted. Afterwards, the chamber door was
closed to exclude room light. We allowed 5 minutes for
the integration of the ICCD camera before images were
acquired.
Luciferase assay
To measure luciferase reporter gene expression in doxy-
cycline induced and un-induced mammary glands of
double transgenic mice, all 5 mammary glands were dis-
sected, rinsed in PBS and tissues were homogenized in
Reporter lysis buffer (Promega, Madison, WI). Insoluble
tissue lysates were removed by centrifugation at 4°C for
5 minutes. Luciferase activity (Rlu) was measured using
10μl of protein lysate, the Luciferase assay kit (Promega,
Madison, WI) and a Berthold luminometer (Berthold
Australia Pty Ltd, Australia). The luciferase readings
were normalized to total protein concentration.
Edu proliferation assay
For assessment of cell proliferation within the mammary
gland, the fourth mammary glands from doxycycline
induced and un-induced double transgenic mice were
harvested at 10.5 days postcoitus (dpc) and 5μmt h i c k
sections were embedded in paraffin. Cell proliferation
was detected using incorporation of 5-ethynyl-2’-deox-
yuridine (EdU) with the Click-iT EdU Cell Proliferation
Assay Kit (Invitrogen, Camarillo, CA), following the
manufacturer’s instructions. EdU that had been incorpo-
rated into newly synthesized DNA was detected by
Alexa Fluor 594 azide (red) and cell nuclei were stained
with Hoechst 33342 (Invitrogen, Camarillo, CA). The
proportion of nucleated cells incorporating EdU was
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Zeiss, Germany). Fifteen random 20× fields were taken
from each group of litter matched doxycycline induced
and un-induced double transgenic mice. The proliferat-
ing cells were quantified and normalized to the total cell
number in each field.
Whole mount analysis
Whole mount preparation of mammary glands was per-
formed at various time points as previously described
[49]. Briefly, mammary glands were removed from doxy-
cycline induced and un-induced double transgenic mice
and fixed overnight in acetic acid/ethanol (1:3) solution.
Fixed mammary glands were then dehydrated using 70%
ethanol for 30 minutes and stained overnight with Car-
mine stain. The mammary glands were then destained,
dehydrated through a series of washes in 70%, 95% and
100% ethanol for 30 minutes each and defatted in
xylene.
Histological staining and immunohistochemistry
The third mammary glands from doxycycline-induced
a n du n - i n d u c e dd o u b l et r a n s g e n i cm i c ew e r ef i x e da n d
embedded in paraffin. Five micrometer thick sections
were deparaffinized with xylene and stained with hema-
toxylin and eosin (H&E) or used for immunohistochem-
istry (IHC). For IHC, antigen retrieval was performed by
treating deparaffinized sections with sodium citrate buf-
fer (pH6) at 95°C for 20 minutes. The sections were
then blocked for one hour with serum followed by an
additional 10 minute blocking with hydrogen peroxide.
Sections were incubated with rabbit anti-TBX3 (Zymed,
Camarillo, CA) and rabbit anti-NFBIB (Santa Cruz Bio-
technology, Santa Cruz, CA) antibodies overnight at 4°C.
The following day, sections were washed in PBS and
incubated with biotinylated goat anti-rabbit IgG (Vector
Laboratories, Burlingame, CA). Standard ABC kit and
DAB kit (Vector Laboratories, Burlingame, CA) were
used for visualization according to the manufacturer’s
instructions.
NFBIB promoter reporter and luciferase assay
The NFKBIB promoter (-2500:+500 bp) was PCR-ampli-
fied from human genomic DNA. The PCR product was
digested and subcloned into the pGL3 luciferase repor-
ter construct (Promega, Madison, WI). COS-7 cells were
transfected with either pcDNA3.1-Myc (control) or
pcDNA3.1-Myc-TBX3 expression vectors together with
the pGL3-NFBIB luciferase reporter construct and a b-
galactosidase control plasmid (pcDNA3.1/His/LacZ)
using Lipofectamine 2000 (Invitrogen, Camarillo, CA).
Cell lysates were harvested 48 hours after transfection.
Luciferase activity was obtained using the Promega
Luciferase Assay System (Promega, Madison, WI)
according to the manufacturer’s guidelines. b-galactosi-
dase enzyme activity was measured using the Promega
b-galactosidase Enzyme Assay System (Promega, Madi-
son, CA) and used to normalize luciferase activity.
Mammary epithelial cell preparation and cell sorting
Mammary epithelial cells were prepared as previously
described with modifications [37]. Briefly, mammary
glands were dissected and mechanically dissociated
with scissors and a Tissue Tearor Homogenizer
(Tearor), followed by enzymatic dissociation (DME/
HAM with 5% BCS, 1 mM L-glutamine, 5μg/ml insu-
lin, 500 ng/ml hydrocortisone, 10 ng/ml epidermal
growth factor, 20 ng/ml cholera toxin, 300μg/ml col-
lagenase, 100μg/ml hyaluranidase) for 5 hours at 37°C.
Cells were pelleted by centrifugation, resuspended in
0.25% trypsin-EDTA and incubated at 37°C for 3 min-
utes. Cells were sequentially incubated with the follow-
ing reagents: 5 mg/ml Dispase (Roche Diagnostics,
Basel, Switzerland) in PBS for 5 minutes, 0.1 mg/ml
DNase in PBS for 5 minutes and 0.64% NH4Cl for 3
minutes at 37°C. Cell suspensions were filtered
through a 40-mm mesh to isolate single cells and were
counted using a hematocytometer.
Mammary cells were then washed with 1 ml Buffer A
(2%FBS, 0.1%NaN3 in PBS) and the cell pellets were
resuspended in 500μl Buffer A. Twenty thousand mam-
mary cells from each mouse were incubated with bioti-
nylated anti-CD31, biotinylated anti-CD45 and
biotinylated anti-TER119 (all 1:1000 dilution) for 15
minutes at room temperature to isolate the Lin+ cells
(stained) from the Lin- cells (unstained). The cells were
washed once with Buffer A and the cell pellets were
resuspended in 150μl Buffer A. The cell suspension was
then incubated with Streptavidin-conjugated APC, PE-
labeled anti-CD24, and FITC conjugated anti-CD29 (all
1:1500) for 30 minutes at 4°C. Cells were washed twice
with Buffer A and resuspended in 500μl Buffer A for
analysis. (Data analysis was performed on the single cell
gate using the demo version of FlowJo software http://
www.flowjo.com/. Cell sorting was carried out on a
Fluorescence-activated cell sorting (FACS) Vantage cell
sorter (Becton Dickinson, Franklin Lakes, NJ). For all
APC conjugated, PE conjugated and FITC conjugated
staining, Mouse IgG (APC), Mouse IgG (PE) and Mouse
IgG (FITC) isotype controls were used.
Animal Use
Animals were maintained in an approved animal facility
and all animal work was carried out in accordance with
t h eU n i v e r s i t yo fC a l i f o r n i aI r v i n eI n s t i t u t i o n a lA n i m a l
Care and Use Committee (IACUC, 2002-2421)....
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